Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 857148, 9 pages
http://dx.doi.org/10.1155/2014/857148
Clinical Study

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

1Department of Ophthalmology, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, West Midlands CV2 2DX, UK
2Institute of Eye Surgery and Macular Pigment Research Group, Whitfield Eye Clinic, Waterford, Ireland
3Department of Ophthalmology, Faculty Hospital, Vojtecha Spanyola 43, 012 07 Zilina, Slovakia
4Hospital Provincial Divino Valles, Avenida Islas Baleares 1, 09006 Burgos, Spain
5Oogcentrum Oostende, Koninginnelaan 54, 8400 Oostende, Belgium
6Novartis Pharma AG, CH-4002 Basel, Switzerland

Received 23 December 2013; Revised 7 March 2014; Accepted 12 March 2014; Published 28 April 2014

Academic Editor: Timothy Y. Lai

Copyright © 2014 Sergio Pagliarini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Lowe, J. Araujo, J. Yang et al., “Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo,” Experimental Eye Research, vol. 85, no. 4, pp. 425–430, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Abraham, H. Yue, and L. Wilson, “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 315–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. S. Boyer, J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio, “A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1731–1739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study,” Ophthalmology, vol. 116, no. 1, pp. 57–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. F. G. Holz, W. Amoaku, J. Donate et al., “Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study,” Ophthalmology, vol. 118, no. 4, pp. 663–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. K. Kaiser, D. S. Boyer, A. F. Cruess, J. S. Slakter, S. Pilz, and A. Weisberger, “Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study,” Ophthalmology, vol. 119, no. 5, pp. 1001–1010, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. O.-W. Kwon, F. L. Lee, H. Chung, C.-C. Lai, S.-J. Sheu, and Y.-H. Yoon, “EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 10, pp. 1467–1476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Larsen, U. Schmidt-Erfurth, P. Lanzetta et al., “Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results,” Ophthalmology, vol. 119, no. 5, pp. 992–1000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. U. Schmidt-Erfurth, B. Eldem, R. Guymer et al., “Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE Study,” Ophthalmology, vol. 118, no. 5, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Tano and M. Ohji, “Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study,” Acta Ophthalmologica, vol. 89, no. 3, pp. 208–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Silva, R. Axer-Siegel, B. Eldem et al., “The SECURE Study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration,” Ophthalmology, vol. 120, no. 1, pp. 130–139, 2013. View at Google Scholar
  13. M. A. Singer, C. C. Awh, S. Sadda et al., “HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration,” Ophthalmology, vol. 119, no. 6, pp. 1175–1183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Y. Cohen, L. Dubois, R. Tadayoni et al., “Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting,” American Journal of Ophthalmology, vol. 148, no. 3, pp. 409–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. Rothenbuehler, D. Waeber, C. K. Brinkmann, S. Wolf, and U. E. K. Wolf-Schnurrbusch, “Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration,” American Journal of Ophthalmology, vol. 147, no. 5, pp. 831–837, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Kumar, J. N. Sahni, A. N. Stangos, C. Campa, and S. P. Harding, “Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy,” British Journal of Ophthalmology, vol. 95, no. 4, pp. 530–533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. R. P. Finger, P. Wiedemann, F. Blumhagen, K. Pohland, and F. G. Holz, “Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany,” Acta Ophthalmology, vol. 91, no. 6, pp. 540–546, 2012. View at Google Scholar
  18. L. Hjelmqvist, C. Lindberg, P. Kanulf, H. Dahlgren, I. Johanssonand, and A. Siewert, “One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study,” Journal of Ophthalmology, vol. 2011, Article ID 405724, 8 pages, 2011. View at Publisher · View at Google Scholar
  19. F. G. Holz, F. Bandello, M. Gillies et al., “Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS program,” British Journal of Ophthalmology, vol. 97, no. 9, pp. 1161–1167, 2013. View at Publisher · View at Google Scholar
  20. J. M. Rakic, A. Leys, J. Brie et al., “Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS Study,” Clinical Ophthalmology, vol. 2013, no. 7, pp. 1849–1858, 2013. View at Google Scholar
  21. B. G. Busbee, A. C. Ho, D. M. Brown et al., “Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration,” Ophthalmology, vol. 120, no. 5, pp. 1046–1056, 2013. View at Google Scholar
  22. U. Chakravarthy, S. P. Harding, C. A. Rogers et al., “Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial,” Ophthalmology, vol. 119, no. 7, pp. 1399–1411, 2012. View at Google Scholar
  23. D. F. Martin, M. G. Maguire, S. L. Fine et al., “Comparison of age-related Macular Degeneration Treatments Trials (CATT) research group,” Ophthalmology, vol. 119, no. 7, pp. 1388–1398, 2012. View at Google Scholar